At ESCRS 2025, Dr. Morgan Micheletti explains why shared experience moves glaucoma care forward faster than any single device or study. In his practice, the iTrack™ Advance plays a key role for mild to moderate disease by preserving the trabecular meshwork, maintaining future treatment options and restoring physiologic outflow with a tissue-sparing approach.
He also highlights the value of a partner that prioritizes science, evidence and outcomes for both surgeons and patients.
Learn more at https://itrack-advance.com/.
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.
